印尼作为东南亚最大经济体，医药市场增长迅速，但药品生产所需原辅料和包装材料高度依赖进口。本次论 坛紧扣印尼市场需求，围绕印尼药品市场现状及准入政策、制药行业需求、中国药品监管体系与医药包装和药用 辅料产业情况等议题进行交流，帮助双方更准确对接合作方向。 人民网雅加达11月20日电 （记者曹师韵）11月20日，2025中印尼医药包装发展论坛在雅加达举行。本次论坛 由中国医药包装协会与印尼制药商协会联合主办，旨在深化中印尼两国在医药包装和药用辅料领域的务实合作， 推动两国产业链对接和经贸交流。来自印尼卫生部、食品和药物管理局、制药企业以及中国医药包装和辅料企业 的约80名代表参会。 中国医药包装协会常务会长蔡弘在致辞中表示，希望借此次论坛推动双方建立长久、稳定的合作关系，"愿双 方以此次交流为起点，让真诚对话滋养友谊，让务实合作生根发芽。" 11月19日，中国代表团还集体走访了多家印尼制药企业及医院等机构，深入生产车间、实验室及诊疗区域， 详细了解印尼制药生产流程、质量管控标准及医药包装实际应用需求，为后续精准合作奠定了坚实基础。 此次论坛为中印尼在医药包装领域搭建了信息共享、技术交流、商业合作的重要平台，有助于 ...

Core Viewpoint - The acquisition of 11.04% equity in Nanjing Pharmaceutical by the buyer, Guangzhou Pharmaceutical Phase II Fund, for RMB 748.8 million, aims to strengthen strategic cooperation between the companies and enhance their competitive advantage in the pharmaceutical distribution industry [1][4]. Group 1: Acquisition Details - The buyer will acquire 11.04% equity in Nanjing Pharmaceutical, with a transaction value of RMB 748.8 million [1]. - Following the acquisition, the buyer will hold 11.04% equity in the target company [1]. Group 2: Strategic Cooperation - A strategic investment agreement has been established to enhance collaboration in capital operations, including potential joint ventures and strategic investments [1]. - The companies will work together to optimize supply chain resources and logistics, focusing on market access and sales for their proprietary industrial products [2]. - Both companies will support the transformation and modernization of traditional Chinese medicine, establishing a comprehensive traceability system for Chinese medicinal materials [3]. Group 3: Company Background - Nanjing Pharmaceutical is a well-known regional enterprise in the pharmaceutical distribution industry, with a market network covering Jiangsu, Anhui, Hubei, Fujian, and Kunming [3]. - The controlling shareholder of Nanjing Pharmaceutical is Nanjing New Industry Group, which holds 44.17% of its shares [3].

Core Viewpoint - Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. announced the acquisition of 11.04% shares of Nanjing Pharmaceutical Co., Ltd. from Alliance Healthcare Asia Pacific Limited for 749 million RMB, making Baiyunshan the second-largest shareholder of Nanjing Pharmaceutical [1][2] Group 1 - The acquisition price is based on the average closing price of Nanjing Pharmaceutical's shares over the previous 60 trading days, set at 5.18 RMB per share [1] - The strategic investment agreement signed includes collaboration in capital cooperation, distribution channels for proprietary industrial products, and cooperation in traditional Chinese medicine [1][2] Group 2 - This transaction is expected to enhance Baiyunshan's business cooperation with Nanjing Pharmaceutical, optimize regional industrial layout, and strengthen competitive advantages in the pharmaceutical distribution business [2] - The Baiyunshan-funded Guangzhou Traditional Chinese Medicine Phase II Fund was established with a total investment of 1.499 billion RMB, focusing on investments in the biopharmaceutical and health sectors [2]